Respiratory News and Research

RSS

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings.

16 Dec 2014

Tips to allergy sufferers for easy breathing this holiday season

The many smells and tastes of the holidays that get so many in a festive mood can sicken others, thanks to allergic reactions. But with some seasonal savvy, allergy sufferers can breathe easy this festive time of year.

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Scientists to explore biology of human asthma by using slime mould

Scientists from Royal Holloway, University of London, will research the biology of human asthma by using a slime mould, an organism which has no lungs but could hold the key to new treatments.

12 Dec 2014

Study: Drive for energy efficient homes could raise asthma risks

The drive for energy efficient homes could increase asthma risks, according to new research.

11 Dec 2014

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.

11 Dec 2014

Study examines benefits of IS technique in assessing effect of pollution on urban asthmatic children

For the firefighters and rescue workers conducting the rescue and cleanup operations at Ground Zero from September 2001 to May 2002, exposure to hazardous airborne particles led to a disturbing "WTC cough" -- obstructed airways and inflammatory bronchial hyperactivity -- and acute inflammation of the lungs. At the time, bronchoscopy, the insertion of a fiber optic bronchoscope into the lung, was the only way to obtain lung samples. But this method is highly invasive and impractical for screening large populations.

11 Dec 2014

Higher human exposure to metal cadmium can lead to shorter telomeres

A new study led by a researcher at Milken Institute School of Public Health at the George Washington University looks at the metal cadmium and finds that higher human exposure can lead to significantly shorter telomeres, bits of DNA at the ends of chromosomes that are associated with cardiovascular disease, diabetes and other diseases of old age.

11 Dec 2014

$Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery$

Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery

The Golden Jubilee National Hospital recently became the first hospital in Scotland to use a revolutionary new technology on a patient suffering from a severe rib fracture.

11 Dec 2014

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found.

9 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.

From Quest Diagnostics 9 Dec 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.

9 Dec 2014

Infant mortality rates for RSV much lower than previously thought

It's a virus that has long been characterized as dangerous and even deadly, but new research shows infant deaths from respiratory syncytial virus (RSV) are actually quite uncommon in the 21st century.

9 Dec 2014

Scientists receive NIH grants to explore sudden unexpected death in epilepsy

Nine groups of scientists will receive funding totaling $5.9 million in 2014 to work together on increasing the understanding of sudden unexpected death in epilepsy (SUDEP), the leading cause of death from epilepsy. The consortium becomes the second Center Without Walls, an initiative to speed the pace of research on difficult problems in epilepsy by promoting collaborative research.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Case Western Reserve is one of two universities in the country selected to lead a $27.3 million international effort to identify the causes of a mysterious and deadly phenomenon that strikes people with epilepsy without warning.

9 Dec 2014

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Aiming to empower planners and policy-makers to achieve better health for billions of people living in fast-growing urban areas, world health, environmental, behavioural and social science experts today launched a major new interdisciplinary scientific collaboration.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Children born prematurely need to be placed in a priority group for seasonal flu vaccination

Children born prematurely are at an increased risk of flu-related complications, despite not being identified as an “at risk” group in UK, USA, or WHO guidelines, and should be a priority group for the seasonal flu vaccination, new research published in The Lancet Respiratory Medicine suggests.

8 Dec 2014

Respiratory News and Research

Roche announces launch of cobas Liat System for on-demand testing in different settings

Tips to allergy sufferers for easy breathing this holiday season

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Scientists to explore biology of human asthma by using slime mould

Study: Drive for energy efficient homes could raise asthma risks

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

Study examines benefits of IS technique in assessing effect of pollution on urban asthmatic children

Higher human exposure to metal cadmium can lead to shorter telomeres

Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Infant mortality rates for RSV much lower than previously thought

Scientists receive NIH grants to explore sudden unexpected death in epilepsy

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Children born prematurely need to be placed in a priority group for seasonal flu vaccination

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News